Lantus is a drug owned by Sanofi Aventis Us Llc. It is protected by 8 US drug patents filed in 2013. Out of these, 2 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2028. Details of Lantus's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7918833 (Pediatric) | Pen-type injector |
Mar, 2028
(3 years from now) | Active |
| US7918833 | Pen-type injector |
Sep, 2027
(2 years from now) | Active |
|
US7476652 (Pediatric) | Acidic insulin preparations having improved stability |
Jan, 2024
(9 months ago) |
Expired
|
|
US7713930 (Pediatric) | Acidic insulin preparations having improved stability |
Dec, 2023
(11 months ago) |
Expired
|
| US7476652 | Acidic insulin preparations having improved stability |
Jul, 2023
(1 year, 4 months ago) |
Expired
|
| US7713930 | Acidic insulin preparations having improved stability |
Jun, 2023
(1 year, 5 months ago) |
Expired
|
|
US5656722 (Pediatric) | A21 -, B30 - modified insulin derivatives having an altered action profile |
Feb, 2015
(9 years ago) |
Expired
|
| US5656722 | A21 -, B30 - modified insulin derivatives having an altered action profile |
Aug, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lantus's patents.
Latest Legal Activities on Lantus's Patents
Given below is the list of recent legal activities going on the following patents of Lantus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2022 | US7918833 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Oct, 2021 | US7713930 (Litigated) |
| Review Certificate Mailed | 05 Jan, 2021 | US7713930 (Litigated) |
| Review Certificate Mailed | 05 Jan, 2021 | US7476652 (Litigated) |
| Review Certificate | 09 Dec, 2020 | US7476652 (Litigated) |
| Review Certificate | 09 Dec, 2020 | US7713930 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Jul, 2020 | US7476652 (Litigated) |
| Termination or Final Written Decision | 12 Dec, 2018 | US7476652 (Litigated) |
| Termination or Final Written Decision | 12 Dec, 2018 | US7713930 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2018 | US7918833 (Litigated) |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Lantus and ongoing litigations to help you estimate the early arrival of Lantus generic.
Lantus's Litigations
Lantus been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 05, 2017, against patent number US7713930. The petitioner Mylan Pharmaceuticals Inc.,, challenged the validity of this patent, with Sanofi Aventis Deutschland GmbH as the respondent. Click below to track the latest information on how companies are challenging Lantus's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7476652 | June, 2017 |
FWD Entered
(12 Dec, 2018) | Sanofi Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc., |
| US7713930 | June, 2017 |
FWD Entered
(12 Dec, 2018) | Sanofi Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc., |
US patents provide insights into the exclusivity only within the United States, but Lantus is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lantus's family patents as well as insights into ongoing legal events on those patents.
Lantus's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lantus's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 23, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lantus Generics:
There are no approved generic versions for Lantus as of now.
Alternative Brands for Lantus
Lantus which is used for managing blood sugar levels in patients with diabetes mellitus., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Glargine Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly |
| |||||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Insulin Glargine Recombinant. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Sanofi Aventis Us |
| ||
| Sanofi Us Services |
|
About Lantus
Lantus is a drug owned by Sanofi Aventis Us Llc. It is used for managing blood sugar levels in patients with diabetes mellitus. Lantus uses Insulin Glargine Recombinant as an active ingredient. Lantus was launched by Sanofi Aventis Us in 2007.
Approval Date:
Lantus was approved by FDA for market use on 27 April, 2007.
Active Ingredient:
Lantus uses Insulin Glargine Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Glargine Recombinant ingredient
Treatment:
Lantus is used for managing blood sugar levels in patients with diabetes mellitus.
Dosage:
Lantus is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100 UNITS/ML | INJECTABLE | Prescription | INJECTION |